JPAD-Journal of Prevention of Alzheimers Disease

Papers
(The H4-Index of JPAD-Journal of Prevention of Alzheimers Disease is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Erratum to: Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats733
Ten Years after the National Alzheimer's Plan: Dementia Remains a Hidden Syndrome in France423
The Geras Solutions Cognitive Test for Assessing Cognitive Impairment: Normative Data from a Population-Based Cohort109
Estimation of the value-based price of a blood test for Alzheimer’s disease pathology in primary and specialty care in the U.S.106
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease96
Neuroprotective Effects of IVIG against Alzheimer's Disease via Regulation of Antigen Processing and Presentation by MHC Class I Molecules in 3xTg-AD Mice82
Effects of Non-Invasive Brain Stimulation on Alzheimer's Disease79
Herpes zoster and dementia : more evidences for a causal link68
Gene and genetic therapies in Alzheimer’s disease and other dementias60
Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau21750
Maximizing the Utility of Alzheimer's Disease Trial Data: Sharing of Baseline A4 and LEARN Data47
‘Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings46
On the 2024 Alzheimer's Association Criteria: Still Not Ready for Clinical Use41
Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation38
Evaluation of Memantine in AAV-AD Rat: A Model of Late-Onset Alzheimer's Disease Predementia38
Validation of the CogDrisk Instrument as Predictive of Dementia in Four General Community-Dwelling Populations38
Informal care for people with dementia in Europe37
Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer’s disease37
LMTK2 and CRB1 are two novel risk genes for Alzheimer's disease in Han Chinese36
AMBAR: A Therapeutical Approach for Alzheimer's Disease Patients Regardless of Amyloid Status36
Introduction to the Special Issue on the A4 Study32
A systematic review of targeted dementia risk reduction interventions in middle-aged adults in Primary Care30
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 630
Projected Savings to Canadian Provincial Budgets from Reduced Long-Term Care Home Utilization Due to a Disease-Modifying Alzheimer's Treatment27
Association between Comorbidity Indices and Functional Autonomy in Individuals with Cognitive Impairment: A Systematic Review26
Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration26
0.36446690559387